Skip to content

Enhanced DPP-GLB to Promote Weight Loss Among Nonresponders in a Community-Based Lifestyle Intervention.

Enhancing the Diabetes Prevention Program to Promote Weight Loss Among Nonresponders in a Community-Based Lifestyle Intervention.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04757519
Enrollment
403
Registered
2021-02-17
Start date
2021-02-18
Completion date
2026-04-17
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Keywords

prevention, weight loss, community, personalized, telephone, resources, lifestyle intervention, racial ethnic minorities / African American, faith based, obesity, non-responders, adults, cancer

Brief summary

This study seeks to establish the efficacy of identifying weight loss nonresponders early in a Diabetes Prevention Program (DPP) intervention in 20 community settings (primarily churches and community centers) and providing them with individual-level, enhanced treatment through telephone contacts and access to additional resources. Additionally, potential mediators and moderators of the relationship between intervention status and weight loss response at 6 months in both nonresponders and responders will be examined and a cost-effectiveness analysis to evaluate the cost of the intervention will be conducted. This study addresses key gaps in the literature about the weight loss effects of identifying nonresponders early and characterizing individuals who need more intense personalized strategies. The investigators hypothesize that changes between baseline and 3 months will be more pronounced among the nonresponders in the intervention group compared to the nonresponders in the active control group.

Interventions

BEHAVIORALDPP-GLB Standard

The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.

BEHAVIORALDPP-GLB Enhanced

The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.

Sponsors

Lovoria Williams
Lead SponsorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* self-described as Black * non-diabetic * body mass index (BMI) equal to or greater than 25 * CDC diabetes risk assessment greater than or equal to 5 or diabetes pre-diagnosis or history of gestational diabetes * live within driving distance of participating church/site

Exclusion criteria

* diagnosed Type 1 or 2 diabetes * pregnant or planning to become pregnant during study period * contraindications to moderate physical activity * serious medical condition that contradicts weight loss * not Black or African American

Design outcomes

Primary

MeasureTime frameDescription
Change in Weight at 12 Weeks12 weeks (at baseline and12 weeks)Weight will be measured in pounds using a cellular scale at baseline and at 12 weeks.
Change in Weight at 6 Months6 months (at baseline and 6 months)Weight will be measured in pounds using a cellular scale at baseline and at 6 months.

Secondary

MeasureTime frameDescription
Change in Blood Pressure at 12 Weeks12 weeks (at baseline and 12 weeks)Blood pressure will be measured with calibrated automated blood pressure monitor at baseline and at 12 weeks.
Change in Blood Pressure at 6 Months6 months (at baseline and 6 months)Blood pressure will be measured with calibrated automated blood pressure monitor at baseline and at 6 months.
Change in Physical Activity at 12 Weeks12 weeks (at baseline and 12 weeks)Change in Physical Activity will be measured at baseline and 12-week using the Modifiable Activity Questionnaire (MAQ), which assesses activity frequency and duration across the leisure and occupational components. Responses were converted to metabolic equivalent hours per week (MET-hrs/week) using standard scoring procedures, where higher MET-hrs/week indicates greater physical activity.
Change in Physical Activity at 6 Months6 months (at baseline and 6 months)Change in Physical Activity will be measured at baseline and 6-month using the Modifiable Activity Questionnaire (MAQ), which assesses activity frequency and duration across the leisure and occupational components. Responses were converted to metabolic equivalent hours per week (MET-hrs/week) using standard scoring procedures, where higher MET-hrs/week indicates greater physical activity.
Change in Dietary Intake at 12 Weeks12 weeks (at baseline and 12 weeks)Change in Dietary Intake will be measured using the validated, Dana Farber eating habits tool and the Dietary screener questionnaire which assesses the frequency of consumption of selected foods and drinks. The scoring range of the survey is Never or less than once per month, 1-3 per month, 1 per week, 2-4 per week, 5-6 per week, 1 per day, 2-3 per day, 4-5 per day, 6 or more per day, Prefer not to answer. Higher scores indicated increased dietary intake. The total score is the sum of the scores on all items, divided by the total maximum score possible, and then multiplied by 100.
Change in Dietary Intake at 6 Months6 months (at baseline, 12 weeks, 6 months)Change in Dietary Intake will be measured using the validated, Dana Farber eating habits tool and the Dietary screener questionnaire which assesses the frequency of consumption of selected foods and drinks. The scoring range of the survey is Never or less than once per month, 1-3 per month, 1 per week, 2-4 per week, 5-6 per week, 1 per day, 2-3 per day, 4-5 per day, 6 or more per day, Prefer not to answer. Higher scores indicated increased dietary intake.The total score is the sum of the scores on all items, divided by the total maximum score possible, and then multiplied by 100.
Cost Analysis6 monthsInvestigator-developed instrument. At 6 months, conduct a cost-effectiveness analysis to evaluate the cost of the intervention arm by comparing the incremental cost and weight loss with the active control arm. The generated final output is the cost per participant in dollars.
Impact of Weight on Quality of Life6 monthsQuality of life will be measured using Impact of Weight on Quality of Life Questionnaire (IWQOL-Lite). This is a 31-item self-report scale. Scores range from 0-100; higher scores indicate greater quality of life.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLovoria Williams

University of Kentucky

Baseline characteristics

Characteristic
Age, Continuous55.9 years
STANDARD_DEVIATION 12.2
College or graduate degree106 Participants
Income > $50,000 annually95 Participants
Married/partnered86 Participants
Private Insurance120 Participants
Race/Ethnicity, Customized
African American / Black
403 Participants
Region of Enrollment
United States
403 participants
Sex: Female, Male
Female
163 Participants
Sex: Female, Male
Male
19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 2030 / 200
other
Total, other adverse events
0 / 2030 / 200
serious
Total, serious adverse events
0 / 2030 / 200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026